Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients

被引：12
|
作者：
Boccadoro, M.
Bringhen, S.
Gaidano, G.
Ria, R.
Offidani, M.
Patriarca, F.
Nozzoli, C.
Musto, P.
Petrucci, M.
Palumbo, A. P.
机构：
[1] Univ Turin, AOUS Giovanni Battista, Div Ematol, Turin, Italy
[2] Univ Piemonte Orientale Amedeo Avogadro, Div Ematol, Novara, Italy
[3] Osped Maggiore La Carita, Novara, Italy
[4] Univ Bari, Dipartimento Sci Biomed & Oncol Umana, Sez Med Interne & Oncol Clin, Bari, Italy
[5] Osped Riuniti Ancona, Azienda Osped Univ, Clin Ematol, Ancona, Italy
[6] Univ Udine, Ist Nazl Tumori & Clin Ematol, Div Ematol, I-33100 Udine, Italy
[7] Univ Florence, AOU Careggi, Dipartimento Ematol, Florence, Italy
[8] CROB, IRCCS, Dipartimento Oncoematol, Rionero In Vulture, Italy
[9] Univ Roma La Sapienza, Osped Umberto 1, Dipartimento Biotecnol Cellulari & Ematol, I-00185 Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.8013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8013
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Clinical Assessment of Bortezomib for Multiple Myeloma in Comparison with Thalidomide
    Satoh, Mitsutoshi
    Oguro, Rieko
    Yamanaka, Chigusa
    Takada, Katsutoshi
    Matsuura, Yasuhiro
    Akiba, Toyomi
    Aotsuka, Nobuyuki
    Tani, Yoshihiro
    Wakita, Hisashi
    [J]. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, 2011, 14 (01): : 78 - 89
  • [42] Bortezomib and thalidomide treatment of newly diagnosed patients with multiple myeloma - Efficacy and neurotoxicity.
    Borrello, Ivan
    Ferguson, Anna
    Huff, Carol Ann
    George, Shirley
    Biedryzcki, Barbara
    Cornblath, David
    Chaudhry, Vinay
    [J]. BLOOD, 2006, 108 (11) : 1006A - 1006A
  • [43] Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma
    Kaufman, Jonathan L.
    Gleason, Charise
    Heffner, Leonard
    Lonial, Sagar
    [J]. BLOOD, 2007, 110 (11) : 1055A - 1055A
  • [44] VAMP/ThaCyDex: Velcade® (Bortezomib), Adriamycin, Melphalan and Prednisone Alternating with Thalidomide, Cyclophosphamide and Dexametasone as a Salvage Regimen in Relapsed Multiple Myeloma Patients.
    Colado, Enrique
    Mateos, Maria-Victoria
    Moreno, Maria-Jose
    Dearriba, Felipe
    de la Rubia, Javier
    Lahuerta, Juan Jose
    Iniesta, Pastora
    Viguria, Maria Cruz
    Gonzalez, Ana Pilar
    Garcia-Sanz, Ramon
    Olazabal, Juan
    Miguel, Jesus F. San
    [J]. BLOOD, 2008, 112 (11) : 1265 - 1266
  • [45] Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment
    Lee, Se Ryeon
    Choi, Hojoon
    Lee, Byung Hyun
    Kang, Ka-Won
    Yu, Eun Sang
    Kim, Dae Sik
    Park, Yong
    Choi, Chul Won
    Kim, Byung Soo
    Sung, Hwa Jung
    [J]. KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (06): : 1333 - 1346
  • [46] THE MAINTENANCE THERAPY WITH THALIDOMIDE IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA
    Bila, J.
    Lekovic, D.
    Smiljanic, M.
    Sretenovic, A.
    Andjelic, B.
    Vidovic, A.
    Todorovic, M.
    Elezovic, I.
    Tomin, D.
    Gotic, M.
    Mihaljevic, B.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 583 - 583
  • [47] Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma
    Palumbo, A
    Avonto, I
    Bruno, B
    Ambrosini, MT
    Bringhen, S
    Cavallo, F
    Falco, P
    Boccadoro, M
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 76 (04) : 273 - 277
  • [48] Erratum: Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant-ineligible patients with multiple myeloma: a meta-analysis
    P Kapoor
    S V Rajkumar
    A Dispenzieri
    M A Gertz
    M Q Lacy
    D Dingli
    J R Mikhael
    V Roy
    R A Kyle
    P R Greipp
    S Kumar
    S J Mandrekar
    [J]. Leukemia, 2011, 25 : 1523 - 1524
  • [49] Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in TransplantIneligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone
    Hou, Jian
    Fu, Weijun
    Bang, Soo-Mee
    Huang, Honghui
    Kim, Kihyun
    Li, Wei
    An, Gang
    Lee, Je-Jung
    Cai, Zhen
    Jin, Jie
    Wang, Yafei
    Chim, C. S.
    Rodriguez-Otero, Paula
    Dimopoulos, Meletios A.
    Fujisaki, Tomoaki
    Lee, Jae Hoon
    Wroblewski, Susan
    Carson, Robin
    Qi, Ming
    Wang, Jianping
    Song, Yang
    Bin Jia
    Yang, Xue
    Liu, Wenyu
    Li, Yunan
    Zhang, Renyi
    Wang, Jianxiang
    [J]. BLOOD, 2021, 138
  • [50] Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade-Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?
    Mateos, Maria-Victoria
    Oriol, Albert
    Martinez, Joaquin
    Cibeira, M. Teresa
    de Paz, Raquel
    Terol, M. Jose
    Garcia-Larana, Jose
    Bengoechea, Enrique
    Martinez, Rafael
    Martin, Alejandro
    de Arriba, Felipe
    Palomera, Luis
    Hernandez, Jose
    Bello, Jose-Luis
    Martin, Maria-Luisa
    Gonazlez, Yolanda
    Blade, Joan
    Jose Lahuerta, Juan
    San Miguel, J. F.
    [J]. BLOOD, 2008, 112 (11) : 243 - 243
12345